Cel Sci (CVM) Retained Earnings (2010 - 2026)
Cel Sci (CVM) posted Retained Earnings of -$550.4 million for Q1 2026, down 1.0% sequentially from -$544.9 million in Q4 2025, and down 4.3% YoY from -$575.1 million in Q1 2025.
Cel Sci (CVM) Retained Earnings (2010 - 2026) Analysis & Trends
Cel Sci has reported Retained Earnings for 17 years, with the latest figure at -$550.4 million in Q1 2026.
- Quarterly Retained Earnings fell 4.3% year-over-year to -$550.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$550.4 million (down 4.3% YoY) and the FY2025 annual result came in at $555.3 million, up 5.4% from the prior year.
- Retained Earnings eased to -$550.4 million in Q1 2026 per CVM's latest filing, from -$544.9 million in the prior quarter.
- Over five years, Retained Earnings peaked at $555.3 million in Q3 2025 and troughed at -$550.4 million in Q1 2026.
- A 5-year average of $36.0 million and a median of $484.7 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings jumped 218.23% in 2022, then tumbled 202.49% in 2025.
- Over 5 years, Retained Earnings stood at -$462.8 million in 2022, then surged by 209.34% to $506.0 million in 2023, then climbed by 5.08% to $531.7 million in 2024, then sank by 202.49% to -$544.9 million in 2025, then decreased by 1.0% to -$550.4 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$550.4 million, -$544.9 million, and $555.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 566.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -550.36 Mn |
| Dec 31, 2025 | -544.89 Mn |
| Sep 30, 2025 | 555.30 Mn |
| Jun 30, 2025 | 540.29 Mn |
| Mar 31, 2025 | -527.66 Mn |
| Dec 31, 2024 | 531.66 Mn |
| Sep 30, 2024 | 526.86 Mn |
| Jun 30, 2024 | -507.90 Mn |
| Mar 31, 2024 | -501.05 Mn |
| Dec 31, 2023 | 505.95 Mn |
| Sep 30, 2023 | 499.83 Mn |
| Jun 30, 2023 | -479.46 Mn |
| Mar 31, 2023 | 490.80 Mn |
| Dec 31, 2022 | -462.75 Mn |
| Sep 30, 2022 | 486.63 Mn |
| Jun 30, 2022 | 484.73 Mn |
| Mar 31, 2022 | -436.80 Mn |
| Dec 31, 2021 | -426.98 Mn |
| Sep 30, 2021 | 474.30 Mn |
| Jun 30, 2021 | -409.99 Mn |